|
[1]
|
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心衰诊断和治疗指南2018 [J]. 中国心血管杂志, 2018, 46(10): 760-789.
|
|
[2]
|
Sandesara, P.B., O’neal, W.T., Kelli, H.M., et al. (2018) The Prognostic Significance of Diabetes and Microvascular Complications in Patients with Heart Failure with Preserved Ejection Fraction. Diabetes Care, 41, 150-155. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guide-lines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treat-ment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the Special Con-tribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 18, 891-975. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Olsson, L.G., Swedberg, K., Ducharme, A., et al. (2006) Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure with and without Left Ventricular Systolic Dysfunction: Results from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Jour-nal of the American College of Cardiology, 47, 1997-2004. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Sartipy, U., Dahlstrom, U., Fu, M., et al. (2017) Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure, 5, 565-574. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Santhanakrishnan, R., Wang, N., Larson, M.G., et al. (2016) Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation, 133, 484-492. [Google Scholar] [CrossRef]
|
|
[7]
|
McManus, D.D., Hsu, G., Sung, S.H., et al. (2013) Atrial Fibrillation and Outcomes in Heart Failure with Preserved versus Reduced Left Ventricular Ejection Frac-tion. Journal of the American Heart Association, 2, e005694. [Google Scholar] [CrossRef]
|
|
[8]
|
Metra, M. and Teerlink, J.R. (2017) Heart Failure. The Lancet, 390, 1981-1995. [Google Scholar] [CrossRef]
|
|
[9]
|
Van Riet, E.E., Hoes, A.W., Limburg, A., et al. (2014) Prev-alence of Unrecognized Heart Failure in Older Persons with Shortness of Breath on Exertion. European Journal of Heart Failure, 16, 772-777. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
李金伟, 邓浪, 严静. 射血分数保留的心力衰竭研究进展[J]. 中国医师进杂志, 2015, 38(6): 465-468.
|
|
[11]
|
Sidney, S., et al. (2019) Association between Aging of the US Population and Heart Disease Mortality from 2011 to 2017. JAMA Cardiology, 4, 1280-1286. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Zafrir, B., Lund, L.H., Laroche, C., et al. (2018) Prognostic Im-plications of Atrial Fibrillation in Heart Failure with Reduced, Mid-Range, and Preserved Ejection Fraction: A Report from 14964 Patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal, 39, 4277-4284. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Clark, D.M., Plumb, V.J., Epstein, A.E., et al. (1997) Hemodynamic Effects of an Irregular Sequence of Ventricular Cycle Lengths during Atrial Fibrillation. American College of Cardiology, 30, 1039-1045. [Google Scholar] [CrossRef]
|
|
[14]
|
Seiler, J., Stevenson, W.G. (2010) Atrial Fibrillation in Con-gestive Heart Failure. Cardiology in Review, 18, 38-50. [Google Scholar] [CrossRef]
|
|
[15]
|
White, C.W., Kerber, R.E., Weiss, H.R., et al. (1982) The Effects of Atrial Fibrillation on Atrial Pressure-Volume and Flow Relationships. Circulation Research, 51, 205-215. [Google Scholar] [CrossRef]
|
|
[16]
|
Ling, L.H., Kistler, P.M., Ellims, A.H., et al. (2012) Diffuse Ven-tricular Fibrosis in Atrial Fibrillation: Noninvasive Evaluation and Relationships with Aging and Systolic Dysfunction. American College of Cardiology, 60, 2402-2408. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Solti, F., Vecsey, T., Kekesi, V., et al. (1989) The Effect of Atrial Dilatation on the Genesis of Atrial Arrhythmias. Cardiovascular Research, 23, 882-886. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Paulus, W.J. and Tschöpe, C. (2013) A Novel Paradigm for Heart Fail-ure with Preserve Dejection Fraction: Coronary Microvascular Endothelial Inflammation. American College of Cardiolo-gy, 62, 263-271. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Sasaki, N., Okumura, Y., Watanabe, I., et al. (2014) Increased Lev-els of Inflammatory and Extracellular Matrix Turnover Biomarkers Persist Despite Reverse Atrial Structural Remodeling during the First Year after Atrial Fibrillation Ablation. Journal of Interventional Cardiac Electrophysiology, 39, 241-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Kotecha, D., Lam, C.S., Van Veldhuisen, D.J., et al. (2016) Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. American College of Cardiology, 68, 2217-2228. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Kjeldsen, S.E., von Lueder, T.G., Smiseth, O.A., et al. (2020) Medical Therapies for Heart Failure with Preserved Ejection Fraction. Hypertension, 75, 23-32. [Google Scholar] [CrossRef]
|
|
[22]
|
Neefs, J., van den Berg, N.W.E., et al. (2020) Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. American Journal of Cardiovascular Drugs, 20, 73-80. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. (2015) Re-gional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldos-terone Antagonist (TOPCAT) Trial. Circulation, 131, 34-42. [Google Scholar] [CrossRef]
|
|
[24]
|
Swedberg, K., Zannad, F., McMurray, J.J., et al. (2012) Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) Study. American College of Cardiology, 59, 1598-1603. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Solomon, S.D., Vaduganathan, M., et al. (2020) Sacu-bitril/Valsartan across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 141, 352-361. [Google Scholar] [CrossRef]
|
|
[26]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895-e1032. [Google Scholar] [CrossRef]
|
|
[27]
|
Hindricks, G., Potpara, T., Dagres, N., et al. (2020) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrilla-tion of the European Society of Cardiology (ESC). European Heart Journal, 42, 373-498.
|
|
[28]
|
Ponikowski, P., Voors, A.A. and Anker, S.D. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiol-ogy (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Zhang, Y.Y., Qiu, C., Davis, P.J., et al. (2013) Predictors of Progression of Recently Diagnosed Atrial Fibrillation in Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation (Record AF)-United States Cohort. American Journal of Cardiology, 112, 79-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Lund, L.H., Benson, L., Dahlstrom, U., et al. (2014) Association between Use of β-Blockers and Outcomes in Patients with heart Failure and Preserved Ejection Fraction. JAMA, 312, 2008-2018. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Ulimoen, S.R., Enger, S., Pripp, A.H., et al. (2014) Calcium Channel Blockers Improve Exercise Capacity and Reduce N-Terminal Pro-B-Type Natriuretic Peptide Levels Compared with Beta-Blockers in Patients with Permanent Atrial Fibrillation. European Heart Journal, 35, 517-524. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Arbelo, E., Brugada, J., Blomstrom-Lundqvist, C., Laroche, C., et al. (2017) On the Behalf of the ESC EHRA Atrial Fibrillation Ablation Long-Term Registry Investigators. Con-temporary Management of Patients Undergoing Atrial Fibrillation Ablation: In-Hospital and 1-Year Follow-Up Findings from the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry. European Heart Journal, 38, 1303-1316. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Noseworthy, P.A., Gersh, B.J., Kent, D.M., et al. (2019) Atrial Fi-brillation Ablation in Practice: Assessing CABANA Generalizability. European Heart Journal, 40, 1257-1264. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Khan, M.N., Jais, P., Cummings, J., et al. (2008) Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart Failure. The New England Journal of Medicine, 359, 1778-1785. [Google Scholar] [CrossRef]
|
|
[35]
|
Lip, G.Y., Nieuwlaat, R., Pisters, R., et al. (2010) Refining Clinical Risk Stratification for Predicting Stroke and Thromboem-Bolismin Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263-272. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 心房颤动基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2020, 19(6): 465-473.
|
|
[37]
|
Savarese, G., Giugliano, R.P., Rosano, G.M., et al. (2016) Efficacy and Safety of Novel Oral Anticoagulants in Patients with Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC: Heart Failure, 4, 870-880. [Google Scholar] [CrossRef] [PubMed]
|